Roche Holding reported CHF30.36B in Sales Revenues for its fiscal semester ending in June of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Alcon AG USD 2.72B 60M Sep/2026
Almirall EUR 602.71M 55.09M Jun/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Bayer EUR 10.05B 820M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Fresenius EUR 5.88B 70M Sep/2026
Fresenius Medical Care EUR 4.94B 80M Sep/2026
Genmab DKK 1.16B 259M Jun/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
GRIFOLS EUR 2.04B 170M Sep/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lakefront Biotherapeutics EUR 7.11M 5M Sep/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.63B 200M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Novartis USD 14.52B 112M Sep/2026
Orion EUR 542.2M 20.6M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Philips EUR 4.4B 40M Sep/2026
Recordati EUR 672M 9.35M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
UCB EUR 4.25B 764M Dec/2025